Ovarian Cancer Presents Moderate Opportunity For Drugmakers

BMI View: Ovarian cancer is not a major health problem in Asia compared with other malignancies. As the region's economies develop over the medium term, the incidence of ovarian cancer will increase, providing commercial upsides to manufacturers of surgical tools, diagnostics and therapeutics. With respective five-year GDP compound annual compound growth rates (CAGRs) of 10.3% and 15.0% in US dollar terms, China and India are the prime investment destinations for healthcare companies addressing ovarian

To read the full article, please choose one of the following options: